Navigation Links
Pfenex Reports Second Quarter 2014 Results and Provides Business Update
Date:8/29/2014

oking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or Pfenex's future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, Pfenex's expectations regarding the development pathway, timing and success of its clinical trials for PF582 and its other product candidates. The Company's expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Pfenex's ability to successfully demonstrate the efficacy and safety of its product candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, Pfenex's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, Pfenex's ability to manage operating expenses, Pfenex's ability to obtain additional funding to support its business activities a
'/>"/>
SOURCE Pfenex Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
2. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
3. Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine
4. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
6. Interleukin Genetics Reports Third Quarter 2011 Financial Results
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Pharmasset Reports Fiscal Year End 2011 Financial Results
10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
11. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... market will grow moderately through 2023 as the aging ... awareness of dental biomaterials all spur procedure volumes. Growth ... China and India ... procedures within reach for a larger proportion of the ...
(Date:12/17/2014)... York, NY (PRWEB) December 16, 2014 ... significant changes since 2013, which is why IBISWorld updated ... this industry continues to benefit from an intensified focus ... the proposal for new emission standards for power plants ... industry operators. According to IBISWorld Industry Analyst Sarah Kahn, ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
Breaking Biology Technology:Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... BARCELONA, Spain , June 14 Data ... in Barcelona , highlights the impact of febrile ... patients. The IMPACT NHL study showed that unplanned hospitalisations, ... to suboptimal relative dose intensity (RDI) of chemotherapy were ...
... ... Mogil, an internationally-renowned leader in pain research, will be presenting “What’s Wrong with ... be held October 4-5, 2010 in Philadelphia, Pennsylvania. , ... Minneapolis, MN (PRWEB) June 10, ...
... ... oldest buildings on earth and a “fascinatingly weird” ancient culture. , ... (PRWEB) June 11, 2010 -- U.S. nonprofit The ... a simple introduction to megalithic architects in Frequently Asked Question format. With content drawn ...
Cached Biology Technology:New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 2New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 3New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 4New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 5New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 6New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 7New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 8New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 9Jeffrey Mogil to Speak on Animal Models of Pain at Arrowhead's 4th Annual Pain Therapeutics Summit 2New tool for exploring the ancient world. 2
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... recently published their joint findings that fatal prion diseases, which ... Findings published this month in the peer-reviewed journal, ... to seven months before an animal shows physical signs of ... brain was being eradicated. This member of the prion family ...
... have demonstrated, for the first time, a graphene-based ... cells and capable of recording the electrical signals ... for further investigation of a promising new material. ... leading contender for future biomedical applications requiring a ...
... Take a Petri dish containing crude petroleum and it ... make up the fossil fuel. Sprinkle mushroom spores over the ... an incubator, and surprise, the petroleum and its smell will ... professor of biological sciences and researcher at the University of ...
Cached Biology News:Medical researchers in Canada and the US discover hidden side of prion diseases 2Biocompatible graphene transistor array reads cellular signals 2Biocompatible graphene transistor array reads cellular signals 3Petroleum-eating mushrooms 2Petroleum-eating mushrooms 3Petroleum-eating mushrooms 4
... suit the widest possible range of sample ... Labware carriers can be placed at any ... for the user, thanks to a numbered ... guided into position. This allows easy removal ...
... Sac-Cel (Second Antibody Coated CELlulose) was developed ... of Dartford, Kent, one of the earliest ... IDS acquired the product range in 1987. ... clinical biochemists developing their own "in house" ...
... N,N- bis- (3-D-Gluconamidopropyl)deoxycholamide ... analog of CHAPS and CHAPSO. Has reduced ... anion exchange chromatography on DEAE-cellulose. Aggregation number: ... Soluble in H 2 O. Aggregation number ...
... N-Dodecyl-N,N-(dimethylammonio)butyrate White crystalline solid. ... to DDMAU (Cat. No. 252005) but differing ... More efficient for the extraction of mycoplasma ... Purity: ≥98% by TLC. Soluble ...
Biology Products: